Clozapine
| Intervention | Outcomes | ||||
|---|---|---|---|---|---|
| Experimental | Control | Immediate | Short term (0–6 weeks) | Medium term (7 weeks to 6 months) | Long term (>6 months) |
| RR = Relative risk—the experimental event rate/control event rate; CI = 95% confidence intervals—an estimate of the precision of RR; ⇓ = decreased; ⇑ = increased; ⇔ = no clear difference. | |||||
| Clozapine51 | Typical antipsychotics | Improved ⇑ (RR=1.6; CI 1.4 to 1.8) | Improved ⇑ (RR=2.1; CI 1.6 to 2.9) | ||
| 1165 participants | 1266 participants | Relapse ⇓ (RR=0.6; CI 0.5 to 0.8) | Relapse ⇓ (RR=0.2; CI 0.1 to 0.3) | ||
| Attrition ⇔ (RR=0.8; CI 0.7 to 1.0) Movement disorders ⇓ (RR=0.7; CI 0.6 to 0.8) Sedation ⇑ (RR=1.3; CI 1.1 to 1.4) Weight ⇑ (RR=1.3; CI 1.0 to 1.5) | Attrition ⇔ (RR=0.6; CI 0.5 to 0.7) | ||||
| Clozapine51 | Typical antipsychotics (treatment resistant illness subgroup) | Improved ⇑ (RR=0.7; CI 0.6 to 0.8) | Improved ⇑ (RR=0.8; CI 0.7 to 0.9) | ||
| 618 participants | 600 participants | Relapse ⇔ (RR=1.0; CI 0.6 to 1.8) Attrition ⇔ (RR=1.2; CI 0.7 to 2) Movement disorders ⇓ (RR=0.8; CI 0.7 to 0.9) Sedation ⇑ (RR=1.2; CI 1.1 to 1.3) Weight ⇑ (RR=1.3; CI 1.0 to 1.6) | Relapse ⇓ (RR=0.2; CI 0.1 to 0.3) Attrition ⇔ (RR=0.6; CI 0.50.7) | ||
| Clozapine53 | Risperidone (treatment resistant illness subgroup) | Improved ⇔ (RR=1.0; CI 0.7 to 1.3) | |||
| 90 participants | 90 participants | Attrition ⇔ (RR=1.0; CI 0.44 to 2.3) Movement disorders ⇔ (RR=1.0; CI 0.2 to 5) Sedation ⇔ (RR=0.9; CI 0.4 to 2.1) Weight ⇔ (RR=0.6; CI 0.3 to 1.2) | |||
| Clozapine53 | Olanzapine (treatment resistant illness subgroup) | Improved ⇔ (RR=0.9; CI 0.7 to 1.1) | |||
| 43 participants | 43 participants | Attrition ⇔ (RR=1.0; CI 0.7 to 1.4) Movement disorders ⇔ (RR=0.8; CI 0.3 to 2) Sedation ⇔ (RR=0.6; CI 0.3 to 1.0) | |||